Health Technology · Pharmaceuticals: Major · NSE: NOVARTIND · data 2026-10-09
Novartis India Limited
Health check: Average (5.5/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹2,049
Market cap
₹4,905 cr
P/E
51.8
P/B
—
ROE
11.6%
ROCE
11.8%
Debt / equity
0
Dividend yield
1.26%
1-year return
196.5%
52-week high
₹2,588.8
52-week low
₹950
Operating margin
27.0%
Growth
| Revenue (last 12 months) | ₹371 cr |
| Net profit (last 12 months) | ₹98 cr |
| Sales growth, 3 years (yearly) | -2.2% |
| Profit growth, 3 years (yearly) | -3.4% |
Similar companies
Orchid Pharma Limited (ORCHPHARMA) · FDC Ltd. (FDC) · Gujarat Themis Biosyn Ltd (GUJTHEM) · RPG Life Sciences Limited (RPGLIFE) · SMS Pharmaceuticals Limited (SMSPHARMA)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open NOVARTIND in NSE Scanner →